BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23

• Press Releases

  ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial

  October 23, 2026

   · 

  10 min read
• Press Releases

  Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease

  October 23, 2026

   · 

  9 min read
• Press Releases

  Biovica Announces Outcome Of The Rights Issue

  October 23, 2026

   · 

  13 min read
• 

  Deals

  Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engager

  Roche will pay Zymeworks $55 million upfront plus another $40 million once the partnership asset enters Phase 1b development and up to $718 million in additional milestones.

  October 23, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

  October 23, 2026

   · 

  9 min read
• Press Releases

  2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS

  October 23, 2026

   · 

  13 min read
• Press Releases

  IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas

  October 23, 2026

   · 

  11 min read
• Press Releases

  Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy

  October 23, 2026

   · 

  14 min read
• Press Releases

  ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET

  October 23, 2026

   · 

  1 min read
• Press Releases

  Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

  October 23, 2026

   · 

  10 min read